Literature DB >> 10952837

Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK)

J Collinson1, M D Flather, K A Fox, I Findlay, E Rodrigues, P Dooley, P Ludman, J Adgey, T J Bowker, R Mattu.   

Abstract

AIMS: To determine characteristics, outcomes, prognostic indicators and management of patients with acute coronary syndromes without ST elevation. METHODS AND
RESULTS: A prospective registry was carried out with follow-up for 6 months after index hospital admission. A history of acute cardiac chest pain was required plus ECG changes consistent with myocardial ischaemia and/or prior evidence of coronary heart disease. Patients with ST elevation or those receiving thrombolytic therapy were excluded. A total of 1046 patients were enrolled from 56 U.K. hospitals. The mean age was 66+/-12 years and 39% were female. The rate of death or non-fatal myocardial infarction at 6 months was 12.2% and of death, new myocardial infarction, refractory angina or re-admission for unstable angina at 6 months was 30%. In a multivariate analysis, patients >70 years had a threefold risk of death or new myocardial infarction compared with those <60 years (P<0.01) and those with ST depression or bundle branch block on the ECG had a five-fold greater risk than those with normal ECG (P<0.001). Aspirin was given to 87% and heparin to 72% of patients in hospital. At 6 months 56% received no lipid-lowering therapy at all. The 6-month rate of coronary angiography was 27% and any revascularization 15%.
CONCLUSIONS: In this cohort there was a one in eight chance of death or myocardial infarction, and a one in three chance of death, new myocardial infarction, refractory angina or re-admission for unstable angina, over 6 months. Age and baseline ECG were useful markers of risk. Aspirin, heparin and statins were not given to about one-sixth, one-third and one-half respectively. Rates of angiography and revascularization appear low. A review of treatment strategies of unstable angina and myocardial infarction without ST elevation is warranted in the U.K. to ensure that patients are receiving optimum treatments to reduce mortality and morbidity. Copyright 2000 The European Society of Cardiology.

Entities:  

Mesh:

Year:  2000        PMID: 10952837     DOI: 10.1053/euhj.1999.1995

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  35 in total

1.  Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond.

Authors:  G Manoharan; A A Adgey
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 2.  Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three?

Authors:  S A Harding; N A Boon; A D Flapan
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

Review 3.  Critical review of unstable angina and non-ST elevation myocardial infarction.

Authors:  P J Sheridan; D C Crossman
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

4.  Revascularisation for acute coronary syndromes: PCI or CABG?

Authors:  J Gunn; D P Taggart
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

Review 5.  British Cardiac Society Working Group on the definition of myocardial infarction.

Authors:  K A A Fox; J Birkhead; R Wilcox; C Knight; J Barth
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

6.  Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP).

Authors:  J S Birkhead; L Walker; M Pearson; C Weston; A D Cunningham; A F Rickards
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

7.  Validation of the GRACE score for prognosis in Indian patients with acute coronary syndromes.

Authors:  Amar R Prabhudesai; M A Srilakshmi; M J Santosh; Gurappa G Shetty; Kiron Varghese; Chandrakant B Patil; Shamanna S Iyengar
Journal:  Indian Heart J       Date:  2012 May-Jun

8.  Reducing transfer times for coronary angiography in patients with acute coronary syndromes: one solution to a national problem.

Authors:  N G Bellenger; T Wells; R Hitchcock; M Watkins; C Duffet; D Jewell; D Palliser; L Shapland; R Curtis; S Scrase; R Burns; N Curzen
Journal:  Postgrad Med J       Date:  2006-06       Impact factor: 2.401

Review 9.  Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.

Authors:  Nick Bosanquet; Bengt Jönsson; Keith A A Fox
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 10.  Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond.

Authors:  S J Walsh; M S Spence; D Crossman; A A J Adgey
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.